A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy

Clinical Pharmacokinetics

Volumn 46, Issue 6, 2007, Pages 471-494

  Loh, Gabriel W ^a   Ting, Lillian S L ^a   Ensom, Mary H H ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; IRINOTECAN; MANNITOL; MELPHALAN; NEDAPLATIN; OXALIPLATIN; PACLITAXEL; PIRARUBICIN; PLATINUM DERIVATIVE; THIOTEPA; TOPOTECAN; VINCRISTINE;

ACCURACY; AREA UNDER THE CURVE; BAYES THEOREM; BLOOD SAMPLING; BLOOD TOXICITY; BONE CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG MONITORING; HUMAN; LUNG CANCER; METASTASIS; MULTIPLE REGRESSION; NEPHROTOXICITY; OROPHARYNX CANCER; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VALIDATION STUDY;

ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BAYES THEOREM; CARBOPLATIN; CHILD; CISPLATIN; DRUG MONITORING; DRUG TOXICITY; FEMALE; HEMATOLOGIC TESTS; HUMANS; MALE; ORGANOPLATINUM COMPOUNDS; REGRESSION ANALYSIS;

EID: 34249741531     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746060-00002     Document Type: Review

References (81)

1. Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 1998 Dec; 56 (6): 1019-38
2. Ranson MR, Scarffe JH. Population and Bayesian pharmacokinetics in oncology. Clin Oncol (R Coll Radiol) 1994; 6 (4): 254-60
3. van den Bongard HJ, Mathot RA, Beijnen JH, et al. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 2000 Nov; 39 (5): 345-67
4. Rousseau A, Marquet P, Debord J, et al. Adaptive control methods for the dose individualisation of anticancer agents. Clin Pharmacokinet 2000 Apr; 38 (14): 315-53
5. Johnsson A, Hoglund P, Grubb A, et al. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus. Cancer Chemother Pharmacol 1996 Nov; 39 (1-2): 25-33
6. Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 2002 Aug; 16 (4): 253-62
7. Nannan Panday VR, van Warmerdam LJ, Huizing MT, et al. A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel. J Cancer Res Clin Oncol 1999 Nov; 125 (11): 615-20
8. Doz F, Urien S, Chatelut E, et al. A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children. Cancer Chemother Pharmacol 1998 Jul; 42 (3): 250-4
9. van Warmerdam LJ, ten Bokkel Huinink WW, Maes RA, et al. Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol 1994; 120 (7): 427-33
10. Panetta JC, Iacono LC, Adamson PC, et al. The importance of pharmacokinetic limited sampling models for childhood cancer drug development. Clin Cancer Res 2003 Nov 1; 9 (14): 5068-77
11. Cole M, Boddy AV, Kearns K, et al. Potential clinical impact of taking multiple blood samples for research studies in pediatric oncology: how much do we really know? Pediatr Blood Cancer 2006 Jun; 46 (7): 723-7
12. Mahmood I. Limited sampling model for the estimation of pharmacokinetic parameters in children. Ther Drug Monit 2000 Oct; 22 (5): 532-6
13. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit 2001 Apr; 23 (2): 100-14
14. Dumont RJ, Ensom MH. Methods for clinical monitoring of cyclosporin in transplant patients. Clin Pharmacokinet 2000 May; 38 (5): 427-47
15. Monchaud C, Rousseau A, Leger F, et al. Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation. Eur J Clin Pharmacol 2003 Apr; 58 (12): 813-20
16. Arizon del Prado JM, Aumente Rubio MD, Cardenas Aranzana M, et al. New strategies of cyclosporine monitoring in heart transplantation: initial results. Transplant Proc 2003 Aug; 35 (5): 1984-7
17. Ting LSL, Villeneuve E, Ensom MHH. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Therap Drug Monit 2006 Jun; 28 (3): 419-30
18. Chattergoon DS, Saunders EF, Klein J, et al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children. Bone Marrow Transplant 1997 Sep; 20 (5): 347-54
19. Baille P, Bruno R, Schellens JH, et al. Optimal sampling strategies for Bayesian estimation of docetaxel (taxotere) clearance. Clin Cancer Res 1997 Sep; 3 (9): 1535-8
20. Di Paolo A, Danesi R, Vannozzi F, et al. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. Clin Pharmacol Ther 2002 Dec; 72 (6): 627-37
21. Gauvin A, Pinguet F, Culine S, et al. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res 2000 Jul; 6 (7): 2690-5
22. Launay MC, Milano G, Iliadis A, et al. A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients. Br J Cancer 1989 Jul; 60 (1): 89-92
23. Marchiset-Leca D, Leca FR, Galeani A, et al. A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans. Cancer Chemother Pharmacol 1995 May; 36 (3): 233-8
24. Mick R, Gupta E, Vokes EE, et al. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol 1996 Jul; 14 (7): 2012-9
25. Yamamoto N, Tamura T, Nishiwaki Y, et al. Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial. Clin Cancer Res 1997 Jul; 3 (7): 1087-92
26. Sloan JA, Atherton P, Reid J, et al. Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide. Cancer Chemother Pharmacol 2001 Sep; 48 (3): 241-9
27. Panetta JC, Wilkinson M, Pui CH, et al. Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia. J Pharmacokinet Pharmacodyn 2002 Apr; 29 (2): 171-88
28. Tranchand B, Amsellem C, Chatelut E, et al. A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 1999 Mar; 43 (4): 316-22
29. Judson I, Kelland LR. New developments and approaches in the platinum arena. Drugs 2000 Jun; 59 Suppl. 4: 29-36
30. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999 Jan; 17 (1): 409-22
31. Huitema ADR, Smits KD, Mathot RA, et al. The clinical pharmacology of alkylating agents in high-dose chemotherapy. Anticancer Drugs 2000 Aug; 11 (7): 515-33
32. Duffull SB, Robinson BA. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 1997 Sep; 33 (3): 161-83
33. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989 Nov; 7 (11): 1748-56
34. Chatelut E, Pivot X, Otto J, et al. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer 2000 Jan; 36 (2): 264-9
35. Newell DR, Pearson AD, Balmanno K, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. J Clin Oncol 1993 Dec; 11 (12): 2314-23
36. Grunkemeier GL, Wu Y. Bootstrap resampling methods: something for nothing? Ann Thorac Surg 2004 Apr; 77 (4): 1142-4
37. Efron B, Gong G. A leisurely look at the bootstrap, the jackknife and cross-validation. Am Stat 1983; 37: 36-48
38. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992 Jun; 22 (5): 447-67
39. Ishizuka N, Ohashi Y. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials. Stat Med 2001 Sep 15-30; 20 (17-18): 2661-81
40. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981 Aug; 9 (4): 503-12
41. US Preventive Services Task Force. Guide to preventive services: report of the US Preventive Services Task Force. 2nd ed. Baltimore (MD): Williams & Wilkins, 1996
42. Izqueirdo MA, Sanchez A, Llort G, et al. Comparison of different methods for AUC dosing of carboplatin (CBDCA). Proc Am Soc Clin Oncol 1996; 16: 204a
43. Riccardi A, Lasorella A, Tornesello A, et al. A single-sample assay for the calculation of free carboplatin AUC in children. Proc Am Soc Clin Oncol 1996; 15: 176
44. Pivot X, Chamorey E, Guardiola E, et al. Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol 2003 Oct; 14 (10): 1578-86
45. Lagrange JL, Medecin B, Etienne MC, et al. Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors. Pharmacotherapy 1997 Nov-Dec; 17 (16): 1246-53
46. Pivot X, Marghali N, Etienne MC, et al. A multivariate analysis for predicting cisplatin-induced delayed emesis. Oncol Rep 2000 May-Jun; 7 (3): 515-9
47. Rubie H, Doz F, Vassal G, et al. Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy. Eur J Cancer 2003 Jul; 39 (10): 1433-8
48. Yamamoto R, Kaneuchi M, Nishiya M, et al. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer. Cancer Chemother Pharmacol 2002 Aug; 50 (2): 137-42
49. Duffull SB, Begg EJ, Robinson BA, et al. A sequential Bayesian algorithm for dose individualisation of carboplatin. Cancer Chemother Pharmacol 1997 Jan; 39 (4): 317-26
50. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995 Apr; 87 (8): 573-80
51. Egorin MJ, Van Echo DA, Olman EA, et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res 1985 Dec; 45 (12 Pt 1): 6502-6
52. de Jonge ME, Huitema AD, Tukker AC, et al. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. Clin Cancer Res. 2005 Jan 1; 11 (1): 273-83
53. Miyazaki M, Fujiwara Y, Takahashi T, et al. Limited-sampling models for estimation of the carboplatin area under the curve. Anticancer Res 1997 Nov-Dec; 17 (6D): 4571-5
54. Asai G, Ando Y, Saka H, et al. Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model. Eur J Clin Pharmacol 1998 Nov-Dec; 54 (9-10): 725-7
55. Guillet P, Monjanel S, Nicoara A, et al. A Bayesian dosing method for carboplatin given by continuous infusion for 120 h. Cancer Chemother Pharmacol 1997 May; 40 (2): 143-9
56. Huitema AD, Mathot RA, Tibben MM, et al. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clin Pharmacol Ther 2000 Jun; 67 (6): 621-30
57. Peng B, Boddy AV, Cole M, et al. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. Eur J Cancer 1995 Oct; 31A (11): 1804-10
58. Sorensen BT, Stromgren A, Jakobsen P, et al. A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 1993 Jul; 31 (4): 324-7
59. Ghazal-Aswad S, Calvert AH, Newell DR. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol 1996 Feb; 37 (5): 429-34
60. Shen M, Schilder RJ, Obasaju C, et al. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support. Cancer Chemother Pharmacol 2002 Sep; 50 (3): 243-50
61. Etienne MC, Leger F, Pivot X, et al. Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance. Ann Oncol 2003 Apr; 14 (4): 643-7
62. Desoize B, Dufour R, Urien S, et al. Evaluation of two dose individualisation methods for carboplatin. Anticancer Res 1996 Jul-Aug; 16 (4A): 2073-8
63. Fournier C, Vennin P, Hecquet B. Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans. Cancer Chemother Pharmacol 1988 Feb; 21 (1): 75-7
64. Monjanel-Mouterde S, Ciccolini J, Bagarry D, et al. Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedback. J Clin Pharm Ther 2003 Apr; 28 (2): 109-16
65. Desoize B, Dumont P, Manot L, et al. Comparison of two dose prediction models for cisplatin. Anticancer Res 1994 Nov-Dec; 14 (6A): 2285-90
66. Ishibashi T, Fukumura K, Yano Y, et al. Optimal sampling and limited sampling strategies for estimation of unbound platinum AUC after nedaplatin infusion. Anticancer Res 2005 Mar-Apr; 25 (2B): 1283-9
67. Johansen MJ, Madden T, Mehra RC, et al. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer. J Clin Oncol 1997 Apr; 15 (4): 1481-91
68. Miyazaki M, Oguri T, Kurata T, et al. Validation of the limited-sampling models for carboplatin AUC in combination chemotherapy with taxanes. Anticancer Res 2004 May-Jun; 24 (3b): 1911-4
69. Panday VR, van Warmerdam LJ, Huizing MT, et al. A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen. Cancer Chemother Pharmacol 1999 Mar; 43 (5): 435-8
70. van Warmerdam LJ, Rodenhuis S, van Tellingen O, et al. Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination. Cancer Chemother Pharmacol 1994 Nov; 35 (2): 179-81
71. Desoize B, Berthiot G, Manot L, et al. Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration. Eur J Cancer 1996 Sep; 32A (10): 1734-8
72. Ishibashi T, Yano Y, Oguma T. A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients. Cancer Chemother Pharmacol 2002 Sep; 50 (3): 230-6
73. O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000 Jun; 59 Suppl. 4: 19-27
74. Favre R, Charbit M, Rinaldi Y, et al. Pharmacokinetics in phase IV studies for the preview of a therapeutic protocol [in French]. Bull Cancer 1988; 75 (6): 541-50
75. Welters MJ, Braakhuis BJ, Jacobs-Bergmans AJ, et al. The potential of platinum-DNA adduct determination in ex vivo treated tumour fragments for the prediction of sensitivity to cisplatin chemotherapy. Ann Oncol 1999 Jan; 10 (1): 97-103
76. Gupta-Burt S, Shamkhani H, Reed E, et al. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Cancer Epidemiol Biomarkers Prev 1993 May-June; 2 (3): 229-34
77. Ishibashi T, Yano Y, Oguma T. Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis. Anticancer Res 2005 Mar-Apr; 25 (2B): 1273-81
78. Ishibashi T, Yano Y, Oguma T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 2003 Aug; 56 (2): 205-13
79. Calvert AH, Egorin MJ. Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Eur J Cancer 2002 Jan; 38 (1): 11-6
80. Chatelut E, Boddy AV, Peng B, et al. Population pharmacokinetics of carboplatin in children. Clin Pharmacol Ther 1996 Apr; 59 (4): 436-43
81. Chevreau C, Thomas F, Couteau C, et al. Ototoxicity of high-dose carboplatin. J Clin Oncol 2005 May; 23 (15): 3649-50